0802 GMT - Novo Nordisk will likely report a strong set of third-quarter results and raise full-year guidance, J. P. Morgan analysts write. The bank forecasts adjusted sales of 76 billion Danish kroner, 4% ahead of Bloomberg consensus. It expects injectable Wegovy sales of 21.5 billion kroner, 9% ahead of consensus, reflecting continued growth in sales outside the U.S. Oral Wegovy sales are seen at 5.3 billion kroner, 19% ahead of views, as it says consensus seems to be underestimating sales outside the U.S. Ozempic sales are seen at 26.6 billion kroner, 7% ahead of consensus. Adjusted operating profit is seen at 30 billion kroner. The bank also expects Novo to raise its constant exchange rate guidance for adjusted sales and adjusted operating profit to minus 3% to plus 1%, from 0% to minus 6%. Shares fall 1.5%.